Arun Swaminathan bought $37k of COYA
Chief Executive Officer at Coya Therapeutics, Inc.. 5,000 shares at an average of $7.36, traded Nov 13, 2024, filed Nov 13, 2024.
Score components
- +25RoleCEO
- +6Trade size$37k at market
- +10Relative to holdingsHoldings up 100%
- 0Price contextNo price history yet
- +15Cluster3 insiders buying within 14 days
- +5Repeat buying2 buys in 90 days
- 0Track recordToo few past buys to judge (0 with prices)
What happened after comparable buys
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
This signal so far: 1m -18.6%, 3m -8.7%, 6m -21.4%.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001493152-24-045120, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Nov 13, 2024 | POpen-market purchase Common Stock, par value $0.0001 per share | +5,000 | $7.36 | $37k | 10,000 | Nov 13, 2024 |
Related signals
Other insiders at Coya Therapeutics, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 43Moderate | Coya Therapeutics, Inc. | David S Snyder Chief Financial Officer | $13k 1,800 shares | +26% | |
| 54Moderate | Coya Therapeutics, Inc. | Arun Swaminathan Chief Executive Officer | $37k 5,000 shares | - | |
| 38Weak | Coya Therapeutics, Inc. | Fred Grossman Chief Medical Officer | $20k 2,710 shares | - |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.